Genetic Classification of iCCA Can Have Significant Prognostic Value

March 2023, Vol 4, No 1

The clinical heterogeneity of intrahepatic cholangiocarcinoma (iCCA) may be a result of multiple cells of origin and variable driver gene alterations; however, certain features are shared with hepatocellular carcinoma (HCC) and extrahepatic CCA (eCCA). A statistical algorithm, the hidden-genome classifier, classifies tumors by identifying tumor genetic origin and integrating multilevel metagenetic information. Dr Yi Song presented results from a retrospective review using the hidden-genome classifier to quantify the genetic heterogeneity of iCCA with a view toward improved tumor classification. Investigators trained and internally validated the hidden-genome classifier using eCCA, gallbladder cancer (GBC), and HCC as extremes on the spectrum.

A retrospective review of patients with biopsy-confirmed iCCA, eCCA, GBC, and HCC was conducted, and a total of 1264 patients were analyzed, 527 with iCCA, 206 with eCCA, 233 with GBC, and 298 with HCC. The iCCA tumors demonstrated a continuous spectrum of alterations similar to eCCA and HCC, ranging from biliary class (122 tumors) to intermediate class (375 tumors) to HCC class (30 tumors).

In patients with unresected iCCA, the median survival ranged from 1 year in the biliary class to 1.8 years in the intermediate class to 2.3 years in the HCC class. In patients who underwent resection, the median survival was 2.4 years in the biliary class, which was lower than both the intermediate class (5.1 years) and the HCC class (4.9 years; Table).

Song Y, et al. Genetic heterogeneity of intrahepatic cholangiocarcinoma: implication for outcome. Poster presented at: ASCO Gastrointestinal Cancer Symposium meeting: January 19-23; San Francisco, CA.

Overall, iCCAs are heterogeneous tumors with a spectrum of genetic alterations with some similarities to HCC and eCCA. Classification of genetic heterogeneity in iCCA may have significant prognostic value.

Source: Song Y, Boerner T, Drill E, et al. Genetic heterogeneity of intrahepatic cholangiocarcinoma: implication for outcome. Poster presented at: ASCO Gastrointestinal Cancers Symposium, January 19-21, 2023; San Francisco, CA. Abstract 595.

Related Items

Tasurgratinib for Patients With FGFR2 Gene Fusion–Positive CCA: A Phase 2 Study
March 2024, Vol 5, No 1
Junji Furuse, MD, PhD, presented the results of a phase 2 study of tasurgratinib efficacy on patients with FGFR2 fusion-positive cholangiocarcinoma following gene fusion status confirmation by fluorescence in situ hybridization.
Safety and Efficacy of Telotristat Ethyl Plus First-Line Chemotherapy in Patients With Advanced BTC: A Phase 2, Open-Label Study
March 2024, Vol 5, No 1
Richard Kim, MD, presented the results of a phase 2, open-label study of patients who underwent telotristat ethyl plus first-line chemotherapy for the treatment of advanced biliary tract cancer.
Efficacy and Safety of Brigimadlin (BI 907828) in Patients With Advanced BTC: Data From 2 Phase 1a/1b Dose-Escalation/Expansion Trials
March 2024, Vol 5, No 1
Teresa Macarulla, MD, PhD, presented the results of 2 phase 1a/1b dose-escalation/expansion trials, studies that measured the efficacy and safety of brigimadlin in patients with advanced biliary tract cancer.
COMPANION-002: A Phase 2/3 Randomized Study Design of CTX-009 Combination in Second-Line BTC
March 2024, Vol 5, No 1
A recombinant bispecific antibody, CTX-009, is discussed regarding its role in an ongoing phase 2/3 open-label, randomized, controlled study—a study being conducted to measure the efficacy of CTX-009 in previously treated, advanced, or metastatic biliary tract cancer.
A Phase 2 Clinical Trial of Anlotinib Plus TQB2450 (PD-L1 Blockade) Plus Nab-Paclitaxel and Cisplatin as First-Line Treatment for Advanced BTC
March 2024, Vol 5, No 1
Cholangiocarcinoma experts presented the preliminary results of a phase 2 clinical trial regarding anlotinib plus TQB2450, nab-paclitaxel, and cisplatin—a study conducted for the treatment of advanced biliary tract cancer.
Preliminary Results of a Real-World Study of the Safety and Efficacy of Surufatinib in BTC
March 2024, Vol 5, No 1
Zongli Zhang, MD, PhD, presented the preliminary results of an ongoing single-arm, multicenter, open-label, real-world study analyzing the efficacy and safety of surufatinib as a second-line treatment option for patients with biliary tract cancer.
Genomic Factors Indicating Sensitivity to IO and Chemotherapy in CCA
March 2024, Vol 5, No 1
Riya Jayesh Patel, MD, presented how the impact of transcriptomic signatures related to chemotherapy and immunotherapy sensitivity in the cholangiocarcinoma (CCA) cohort of The Cancer Genome Atlas could serve as evidence supporting the effectiveness of metabolism-targeted therapies in overcoming CCA therapeutic resistance.
Examining Real-World Testing, Treatment Patterns, and Outcomes After Liquid Biopsy in aCCA
March 2024, Vol 5, No 1
Amit Mahipal, MD, presented results from a real-world data study examining the rates of molecular alterations detected using circulating tumor DNA (ctDNA) for patients receiving ivosidenib following circulating tumor ctDNA-detected IDH1 mutations.
A Phase 2 Primary Analysis of Tislelizumab Plus Lenvatinib and GEMOX as Conversion Therapy in Potentially Resectable Locally Advanced BTC (ZSAB-TransGOLP)
March 2024, Vol 5, No 1
Jia Fan, PhD, presented results from a phase 2 trial that investigated the efficacy and safety of lenvatinib and a programmed cell death protein-1 antibody as conversion therapy for the treatment of potentially resectable and locally advanced biliary tract cancer.
Role of CD27 Agonist in Combination With PD-L1 and MEK Inhibition on Antitumor Effect and CD8+ T Cells: Expanding Immunotherapy Options in CCA
March 2024, Vol 5, No 1
Frances J. Bennett, MD, presented the results of a phase 2 trial that tested the antitumor effect of dual programmed death-ligand 1 plus mitogen-activated protein kinase inhibition in patients with advanced biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: